Jun92022UncategorizedCategory: UncategorizedBy Charlotte Maddalena9 June 2022 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancerNextNext post:First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®Related PostsOrphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024ORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024
Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024
ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
